Glaucoma is characterized by a group of eye diseases in which damage to the optic nerve leads to vision loss.
There are several types of glaucoma and the mechanism of optic nerve damage varies between types, but the most common type (open-angle glaucoma) results from increased intraocular pressure within the eye.
Conventional treatment for glaucoma includes medication to decrease eye pressure, laser treatment, and surgery.
Stem cell research for Glaucoma is focused on trying to regenerate or repair optic nerve damage that has occured as a result of increased eye pressure.
If you would like to talk with an expert about your specific condition, please fill out the
The most current research regarding stem cells and Glaucoma is given below:
Stem Cell Therapy in Glaucoma
Hany M. El-ibiary , Lamia S. Elewa , Maha M. Ibrahim , Eman M. Wady
Abstract: Glaucoma is a chronic, degenerative optic neuropathy, which cause progressive damage to the optic nerve, retinal ganglion cell (RGC) death and characteristic damage to the visual field. Current glaucoma therapeutics lower intraocular pressure (IOP) but they do not repair the damaged optic nerve or reverse vision loss. So, new treatment strategies are in demand. Stem cell therapy presents a new intervention that holds great promise for reversing vision loss. There are at least 3 potential targets for stem cell therapy in glaucoma: the retinal ganglion cells, the optic nerve head, and the trabecular meshwork. Stem cells also have a neuroprotective effect in glaucoma by improving retinal ganglion cell survival. There are many obstacles in using stem cells in glaucoma as the regulation of differentiation, integration, host immune response, tumorigenesis and ethical concerns.